Atenolol
- Generic Name
- Atenolol
- Brand Names
- Tenoretic, Tenormin
- Drug Type
- Small Molecule
- Chemical Formula
- C14H22N2O3
- CAS Number
- 29122-68-7
- Unique Ingredient Identifier
- 50VV3VW0TI
- Background
Atenolol is a cardioselective beta-blocker used in a variety of cardiovascular conditions.
...
- Indication
Indicated for:
1) Management of hypertension alone and in combination with other antihypertensives.
2) Management of angina pectoris associated with coronary atherosclerosis.
3) Management of acute myocardial infarction in hemodynamically stable patients with a heart rate greater than 50 beats per minutes and a systolic blood pressure above 100 mmHg.
...
- Associated Conditions
- Alcohol Withdrawal Syndrome, Angina Pectoris, Atrial Fibrillation, Heart Failure, Hypertension, Migraine, Myocardial Infarction, Refractory Hypertension, Secondary prevention Myocardial infarction, Supra-ventricular Tachyarrhythmias, Thyrotoxicosis, Ventricular Tachyarrhythmias
- Associated Therapies
- -
Hypertension in Hemodialysis Patients (Aim 3)
- Conditions
- Interventions
- First Posted Date
- 2007-12-28
- Last Posted Date
- 2016-01-18
- Lead Sponsor
- Indiana University
- Target Recruit Count
- 200
- Registration Number
- NCT00582114
- Locations
- 🇺🇸
Indiana University, Indianapolis, Indiana, United States
Nephropathy In Type 2 Diabetes and Cardio-renal Events
- First Posted Date
- 2007-09-27
- Last Posted Date
- 2020-08-03
- Lead Sponsor
- University of Campania "Luigi Vanvitelli"
- Target Recruit Count
- 850
- Registration Number
- NCT00535925
- Locations
- 🇮🇹
Department of Advanced Medical and Surgical Sciences, Università della Campania "Luigi Vanvitelli", Naples, Italy, Naples, Italy
Effect of the Angiotensin II Receptor Antagonist Irbesartan on Biochemical and Functional Markers of Endothelial Dysfunction in Patients With Hypertension
- First Posted Date
- 2007-09-14
- Last Posted Date
- 2011-01-12
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 108
- Registration Number
- NCT00529750
Elder Surgery - Functional Recovery Following Beta Blockade
- First Posted Date
- 2007-07-26
- Last Posted Date
- 2016-03-16
- Lead Sponsor
- Icahn School of Medicine at Mount Sinai
- Target Recruit Count
- 359
- Registration Number
- NCT00507663
- Locations
- 🇺🇸
NYU School of Medicine, New York, New York, United States
🇺🇸The Mayo Clinic, Rochester, Minnesota, United States
🇺🇸Icahn School of Medicine at Mount Sinai, New York, New York, United States
Comparison of Two Medications Aimed at Slowing Aortic Root Enlargement in Individuals With Marfan Syndrome--Pediatric Heart Network
- First Posted Date
- 2007-01-31
- Last Posted Date
- 2015-04-01
- Lead Sponsor
- Carelon Research
- Target Recruit Count
- 608
- Registration Number
- NCT00429364
- Locations
- 🇺🇸
Washington University School of Medicine, St Louis, Missouri, United States
🇺🇸Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸Lucile Packard Children's Hospital, Palo Alto, California, United States
Safety and Efficacy of Valsartan vs Atenolol and Hydrochlorothiazide Combination on Blood Flow in Hypertensive Patients
- Conditions
- Interventions
- First Posted Date
- 2006-11-07
- Last Posted Date
- 2011-06-06
- Lead Sponsor
- Novartis
- Target Recruit Count
- 30
- Registration Number
- NCT00396656
- Locations
- 🇨🇭
Novartis Pharma Ag, Basel, Switzerland
Irbesartan and Atenolol in Hypertensive Heart Disease
- First Posted Date
- 2006-10-18
- Last Posted Date
- 2015-05-05
- Lead Sponsor
- Karolinska Institutet
- Target Recruit Count
- 115
- Registration Number
- NCT00389168
- Locations
- 🇸🇪
Karolinska Institutet, Daprtment of Clinical Sciences, Danderyd Hospital, Cardiovascular Research Laboratory, Stockholm, Sweden
Pharmacogenomic Evaluation of Antihypertensive Responses
- First Posted Date
- 2005-10-30
- Last Posted Date
- 2018-05-07
- Lead Sponsor
- University of Florida
- Target Recruit Count
- 1701
- Registration Number
- NCT00246519
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸University of Florida Department of Community Health and Family Medicine, Gainesville, Florida, United States
🇺🇸Emory University, Atlanta, Georgia, United States
Perioperative Effect of Atenolol on Cytokine Profiles
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2008-06-17
- Lead Sponsor
- Saini Foundation
- Target Recruit Count
- 60
- Registration Number
- NCT00202358
- Locations
- 🇺🇸
Cape Cod Hospital, Hyannis, Massachusetts, United States
A Comparison of the Effect of Olmesartan Medoxomil, Losartan Potassium, and Atenolol on the Ability of Overweight Patients With High Blood Pressure to Respond to Insulin
- Conditions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2005-12-23
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 60
- Registration Number
- NCT00185094
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.